May 19, 2014 — GE Healthcare and CorTechs Labs announced the signing of a strategic joint-marketing agreement at the joint meeting of the International Society of Magnetic Resonance in Medicine (ISMRM) and the European Society of Magnetic Resonance in Medicine and Biology (ESMRMB), held in Milan. The companies will collaborate to co-market an MRI (magnetic resonance imaging) scanning solution combined with NeuroQuant, CorTechs Labs’ MRI post-processing application.
NeuroQuant enables the acquisition of volumetric brain image data and automatically conducts accurate and consistent measurements of cortical and subcortical volumes targeted at identifying evidence of neurodegeneration. This innovative solution will provide neurologists and radiologists with objective support for their clinical impression.
“Accurate measurement of volumes of different parts of the brain may be a useful aid in the diagnosis of neurodegenerative diseases such as Alzheimer’s, multiple sclerosis and traumatic brain injury," said Chris Airriess, chief technology officer, CorTechs Labs. "Volume changes in certain brain structures have been linked in the literature to early indications of such conditions where more traditional diagnoses lack detection sensitivity.”
NeuroQuant does this in an automated fashion, without user intervention, and is the only U.S. Food and Drug Administration (FDA) 510(k) approved software for this application.
“CorTechs Labs is a pioneer and a trendsetter in the area of software for the aid of brain diagnostics and is widely used in clinical practices worldwide,” said Baldev Ahluwalia, premium segment manager at GE Healthcare, MRI. “We at GE Healthcare look forward to collaborating with CorTech Labs, benefitting from their innovative approach to providing the highly desired quantitative brain volumetric information with NeuroQuant.”
"We're pleased to expand our relationship with GE Healthcare,” said Guri Stark, CEO of CorTechs Labs. “We look forward to working with GE Healthcare to empower clinicians with objective quantitative data, while continuing NeuroQuant’s growth momentum. In turn, this furthers our vision to establish NeuroQuant as the standard measurement solution for all brain disorders, including Alzheimer’s disease, epilepsy, multiple sclerosis and traumatic brain injury."